MilliporeSigma Announces New U.S. Hub for Merck

Jul 20, 2016

MilliporeSigma plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck KGaA, Darmstadt, Germany. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

“This new and more expansive MilliporeSigma campus gives us a unique, multi-use life science hub in the United States—one that provides our employees and customers with a sustainable and collaborative working environment,” said Udit Batra, Member, Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. “We have a long history in the Commonwealth, and as a global leader in life science, we are committed to strengthening our presence in one of the most important science and technology hubs in the world.”

The campus will serve as a premier global customer destination, housing both a customer service and call center and an M Lab Collaboration Center—a state-of-the-art, shared, exploratory environment where the company’s scientists and engineers work together with customers to help solve their toughest life science challenges. The M Lab Collaboration Center will be one of nine centers worldwide created specifically for collaboration, where hands-on training, customer experiments and application troubleshooting take place in a non-GMP environment. Other locations will include Brazil, China, France, India, Singapore and South Korea. This new enhanced M Lab Collaboration Center in Burlington will replace the flagship M Lab at the company’s Billerica facility.

MilliporeSigma’s 850 full-time Billerica-based employees will relocate to the new campus when construction is complete in the second half of 2017.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments